Local Prescribing Information (Oncology):

Atezolizumab Injection [Tecentriq^®]

Bevacizumab Injection [Avastin^® and Syndyma^®]

Obinutuzumab Injection [Gazyva^®]

Trastuzumab for Injection [Herclon^™ and Biceltis^®]

Trastuzumab emtansine for Injection [Kadcyla^®]

Pertuzumab Injection [Perjeta^®]

Rituximab Injection [Ristova^® and Ikgdar^®]

Alectinib Capsules [Alecensa^®]

Erlotinib Tablets I.P. [Tarceva^®]

Capecitabine Tablets I.P. [Xeloda^®]

Safety Update Information for Healthcare Professionals (Oncology):

DHPC package issued for Tecentriq regarding SCARs (Severe Cutaneous Adverse Reactions) an Identified Risk dated 6th Nov 2020

5-Fluorouracil (i.v.), Capecitabine and Tegafur containing products: Pre-treatment testing to identify DPD deficient patients at increased risk of severe toxicity dated 19th May 2020

DHPC Tecentriq Atezolizumab Injection 1200mg/20ml Safety Update Identified risk -Immune-related myositis dated 31st January 2019

DHPC Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated 3rd October 2018

DHPC Tecentriq Atezolizumab Injection 1200mg/20ml Important Identified risk immune related nephritis dated 30th July, 2018

DHPC Tecentriq Atezolizumab Injection 1200MG/20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated July 23, 2018